samedan logo
 
 
 
spacer
home > ebr > spring 2019 > connecting erp and rim data
PUBLICATIONS
European Biopharmaceutical Review

Connecting ERP and RIM Data

The more readily different parts of life sciences organisations can share good quality data, the greater the benefits for everyone concerned. However, all of this relies on an ability to harness the right data at the right time as a useful asset. As long as data is entered in different ways into different systems and in functional siloes, the scope for improving productivity and efficiency and delivering strategic business benefits will be limited. What other options are available and what is involved in a ‘master data management’ approach?

Improved data exchange was the subject of a recent roundtable debate among experienced industry experts. On the panel were Steve Gens, managing partner at Gens & Associates, Kelly Hnat, Principal at K2 Consulting, Jesper Kihl, Vice President for Global Regulatory Affairs at LEO Pharm, Jan Vindberg-Larsen, Senior Director and Head of Global Regulatory Affairs at Lundbeck, Erick Gaussens PhD, Chief Scientific Officer at ProductLife Group (PLG), Catherine Gambert, Senior Consultant for Regulatory Affairs and Regulatory Information at PLG, and Loetitia Jabri, Regulatory and Pharmaceutical Platforms Associate Director at PLG.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Erick Gaussens PhD is co-founder, Principal Consultant, and Chief Scientific Officer at ProductLife Group, providing deep insights into risk management and regulatory sciences in the life sciences industry, as well as expertise in cognitive science.
spacer
Eric Gaussens PhD
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

First own Gerresheimer Autoinjector - Gerresheimer and Midas Pharma announce strategic partnership

– Gerresheimer’s first own IP autoinjector suitable for both small and large molecules enhances broad portfolio of solutions, medical devices and pharmaceutical primary packaging – First joint project of Gerresheimer and Midas Pharma: Development and marketing of new autoinjector – One-stop-shop for biotech and pharma customers Duesseldorf, November 08, 2021 – Gerresheimer acquired the IP of a new generation cartridge based autoinjector from Midas Pharma. This is the start of a strategic partnership. The joint project comprises the development and marketing of the new generation autoinjector.
More info >>

White Papers

Planning the Execution of a Viral Clearance Study

Eurofins BioPharma Product Testing

Viral clearance studies are a necessary component of any regulatory submission for clinical trials or commercial product approval for all biopharmaceutical products. These studies are performed to evaluate the capability of the purification process to remove or inactivate viruses that could potentially contaminate the starting material. They are complex studies that require substantial financial and personnel resources, as well as specialized scientific expertise to perform. As such, viral clearance studies are often performed at a qualified contract testing laboratory rather than in-house. When multiple parties are involved in this process, clear communication and a comprehensive understanding of the approach and timeline is critical.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement